NCT04809805View on ClinicalTrials.gov

A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

November 9, 2022

Study Completion Date

April 27, 2023

Conditions
Metastatic Melanoma and Other Solid Tumors
Interventions
DRUG

BAY2666605

One oral solution strength of BAY2666605 will be used. Two different tablet strengths of BAY2666605 will be available.

Trial Locations (3)

37203

Sarah Cannon Development Innovations, Nashville

77030

University of Texas MD Anderson Cancer Center, Houston

Texas

"South Texas Accelerated Research Therapeutics , START San Antonio"

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT04809805 - A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer | Biotech Hunter | Biotech Hunter